Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma Intervention: Drug: Zanubrutinib, Polatuzumab vedotin and Rituximab Sponsor: Peng Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2023 Category: Research Source Type: clinical trials
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma Intervention: Drug: Zanubrutinib, Polatuzumab Vedotin, Rituximab Sponsor: Peng Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2023 Category: Research Source Type: clinical trials
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma Intervention: Drug: Zanubrutinib, Polatuzumab vedotin and Rituximab Sponsor: Peng Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2023 Category: Research Source Type: clinical trials
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma Intervention: Drug: Zanubrutinib, Polatuzumab Vedotin, Rituximab Sponsor: Peng Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2023 Category: Research Source Type: clinical trials
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma Intervention: Drug: Zanubrutinib, Polatuzumab vedotin and Rituximab Sponsor: Peng Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2023 Category: Research Source Type: clinical trials
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma Intervention: Drug: Zanubrutinib, Polatuzumab Vedotin, Rituximab Sponsor: Peng Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2023 Category: Research Source Type: clinical trials
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma Intervention: Drug: Zanubrutinib, Polatuzumab vedotin and Rituximab Sponsor: Peng Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2023 Category: Research Source Type: clinical trials
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Conditions: Diffuse Large B Cell Lymphoma; Transformed Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma Interventions: Drug: FT596; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone; Drug: Rituximab; Drug: Bendamustine Sponsor: Fate Therapeutics Withdrawn (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2023 Category: Research Source Type: clinical trials
